Familial hypercholesterolaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PCSK9 14
• APOE 1
• PPAR 0
• ANGPTL3 3
• CD40 0
• AMPK 0
• MAPK 0
• TP53 0
• NRF2 0
• TNF 0
• BCL-2 0
• ERK 0
• mTOR 0
• NLRP3 1
• ALK 0
• EGFR 0
• GLP-1 1
• HER2 0
• IL-6 0
• JNK 0
• SIRT1 0
• STAT3 0
• STING 0
• YAP 0
• BDNF 0
• BRCA1 0
• BRCA2 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0
• HMGB1 0
• IL-17 0
• JAK 0
• KRAS 0
• LAG-3 0
• MDM2 0
• MEK 0
• PD-L1 0
• PSMA 0
• ROS1 0
• TLR4 0
• VEGF 0

EU-13 is a filter, not a ranking: it only narrows the list.

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Immunomodulatory Effects of PCSK9 Inhibition

  NCT05720156· Massachusetts General Hospital· Updated 26 Sept 2025

  “Lack of Feasibility”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

  NCT07058077· Merck Sharp & Dohme LLC· Source

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Novartis Pharmaceuticals· Source

• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

  NCT05952856· Merck Sharp & Dohme LLC· Source

• A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

  NCT07803679· Amgen· Source

• A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

  NCT07610278· Novartis Pharmaceuticals· Source

• A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Novartis Pharmaceuticals· Source

• A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT06386419· Novartis Pharmaceuticals· Source

• Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

  NCT07581808· University Medical Centre Ljubljana· Source

• Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Novartis Pharmaceuticals· Source

• A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

  NCT06450366· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 7
• Gene Expression Profiling 15
• Whole Genome Sequencing 4
• Exome Sequencing 11
• Proteomics 6
• Metabolomics 5
• Mass Spectrometry 5
• Flow Cytometry 13
• Immunohistochemistry 18
• Xenograft Model Antitumor Assays 8
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 17
• Machine Learning 7
• Cohort Studies 74
• Genome-Wide Association Study 8

• Diagnosis of familial hypercholesterolemia through population screening.

  Expert Rev Cardiovasc Ther, Sept 2026

• Machine Learning Triage of LDLR Variants of Uncertain Significance Using Predictor Concordance and ACMG-Aligned Evidence Mapping.

  Genes (Basel), Aug 2026

• Potential Shared Immunometabolic Signatures Between Familial Hypercholesterolemia and Major Depressive Disorder: Integrative Transcriptomic Analysis, Mendelian Randomization, and Clinical Validation.

  Int J Mol Sci, Aug 2026

• Leveraging machine learning with real-world data for hypothesis generation by identifying exposomic predictors in Parkinson's disease among farmers.

  J Parkinsons Dis, Aug 2026

• Machine learning-based identification of cardiovascular risk modifiers in patients with very high LDL cholesterol: A cross-sectional study.

  Medicine (Baltimore), Jul 2026

• Identification of lipid metabolism-related biomarkers in familial hypercholesterolemia via integrated bioinformatics and machine learning approaches.

  J Cardiothorac Surg, Apr 2026

• Integrating administrative health data and machine learning to predict ALS onset.

  Amyotroph Lateral Scler Frontotemporal Degener, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.